MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels
Author Information
Author(s): Wulfken Lena M., Moritz Rudolf, Ohlmann Carsten, Holdenrieder Stefan, Jung Volker, Becker Frank, Herrmann Edwin, Walgenbach-Brünagel Gisela, von Ruecker Alexander, Müller Stefan C., Ellinger Jörg
Primary Institution: Universitätsklinikum Bonn
Hypothesis
Circulating microRNAs could serve as diagnostic/prognostic biomarkers for renal cell carcinoma (RCC) patients.
Conclusion
Circulating miR-1233 is identified as a potential biomarker for RCC patients.
Supporting Evidence
- MicroRNA levels are distinctly increased in cancer patients.
- Only a small subset of circulating microRNAs has a tumor-specific origin.
- Larger-scaled studies are warranted to fully explore the role of circulating microRNAs in RCC.
Takeaway
Doctors are looking at tiny molecules in the blood called microRNAs to help find kidney cancer. One of these, called miR-1233, seems to be a good clue for spotting the disease.
Methodology
The study analyzed serum microRNA levels in RCC patients and healthy controls using quantitative real-time PCR.
Potential Biases
The control group consisted of younger healthy individuals, which could introduce bias.
Limitations
The study had a limited sample size in the initial phases and did not correlate miR-1233 levels with clinical-pathological parameters.
Participant Demographics
The study included 84 RCC patients and 93 healthy controls, with a mix of male and female participants.
Statistical Information
P-Value
0.022
Confidence Interval
95%CI 1.57-2.81
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website